tetano
Editor, Senior Moderator
Brain Commun
. 2020 Sep 17;2(2):fcaa149.
doi: 10.1093/braincomms/fcaa149. eCollection 2020.
Neurological manifestations of severe acute respiratory syndrome coronavirus 2-a controversy 'gone viral'
Moritz F?rster[SUP] 1 [/SUP], Vivien Weyers[SUP] 1 [/SUP], Patrick K?ry[SUP] 1 [/SUP], Michael Barnett[SUP] 2 [/SUP], Hans-Peter Hartung[SUP] 1 [/SUP], David Kremer[SUP] 1 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 first appeared in December 2019 in Wuhan, China, and developed into a worldwide pandemic within the following 3 months causing severe bilateral pneumonia (coronavirus disease 2019) with in part fatal outcomes. After first experiences and tentative strategies to face this new disease, several cases were published describing severe acute respiratory syndrome coronavirus 2 infection related to the onset of neurological complaints and diseases such as, for instance, anosmia, stroke or meningoencephalitis. Of note, there is still a controversy about whether or not there is a causative relation between severe acute respiratory syndrome coronavirus 2 and these neurological conditions. Other concerns, however, seem to be relevant as well. This includes not only the reluctance of patients with acute neurological complaints to report to the emergency department for fear of contracting severe acute respiratory syndrome coronavirus 2 but also the ethical and practical implications for neurology patients in everyday clinical routine. This paper aims to provide an overview of the currently available evidence for the occurrence of severe acute respiratory syndrome coronavirus 2 in the central and peripheral nervous system and the neurological diseases potentially involving this virus.
Keywords: COVID-19; SARS-CoV-2; neurological manifestations.
. 2020 Sep 17;2(2):fcaa149.
doi: 10.1093/braincomms/fcaa149. eCollection 2020.
Neurological manifestations of severe acute respiratory syndrome coronavirus 2-a controversy 'gone viral'
Moritz F?rster[SUP] 1 [/SUP], Vivien Weyers[SUP] 1 [/SUP], Patrick K?ry[SUP] 1 [/SUP], Michael Barnett[SUP] 2 [/SUP], Hans-Peter Hartung[SUP] 1 [/SUP], David Kremer[SUP] 1 [/SUP]
Affiliations
- PMID: 33210085
- PMCID: PMC7543269
- DOI: 10.1093/braincomms/fcaa149
Abstract
Severe acute respiratory syndrome coronavirus 2 first appeared in December 2019 in Wuhan, China, and developed into a worldwide pandemic within the following 3 months causing severe bilateral pneumonia (coronavirus disease 2019) with in part fatal outcomes. After first experiences and tentative strategies to face this new disease, several cases were published describing severe acute respiratory syndrome coronavirus 2 infection related to the onset of neurological complaints and diseases such as, for instance, anosmia, stroke or meningoencephalitis. Of note, there is still a controversy about whether or not there is a causative relation between severe acute respiratory syndrome coronavirus 2 and these neurological conditions. Other concerns, however, seem to be relevant as well. This includes not only the reluctance of patients with acute neurological complaints to report to the emergency department for fear of contracting severe acute respiratory syndrome coronavirus 2 but also the ethical and practical implications for neurology patients in everyday clinical routine. This paper aims to provide an overview of the currently available evidence for the occurrence of severe acute respiratory syndrome coronavirus 2 in the central and peripheral nervous system and the neurological diseases potentially involving this virus.
Keywords: COVID-19; SARS-CoV-2; neurological manifestations.